title: The costs of managing patients with malignant glioma at a neuro-oncology clinic.
abstract: Malignant glioma (glioblastoma and anaplastic astrocytoma) remain incurable despite extensive resection, radiotherapy, chemotherapy and experimental therapies. Few studies have addressed either the costs of various treatments for malignant glioma or their cost effectiveness. The aims of this study were to identify direct hospital costs of treating patients with biopsy proven malignant glioma. The study was carried out within the setting of a dedicated neuro-oncology clinic at a university teaching hospital and included 236 patients treated between 1989 and 1995. The study used the unit costing of each item of treatment according to NHS National Costing Project. The cost of treatment was broken down into its various components: bed days, investigations, surgery, radiotherapy, chemotherapy and neuro-oncology out-patient follow-ups. The mean costs for each of the items based on 1995 figures for the 157 patients having surgery followed by radiotherapy were neuroradiological investigations (442 Pounds), neurosurgical bed days (2407 Pounds), neurosurgery (2068 Pounds), neuropathology (434 Pounds), radiotherapy (8832 Pounds), out-patients (1078 Pounds) and chemotherapy (440 Pounds). Total treatment costs per patient ranged from 1978 Pounds to 26,980 Pounds. Median costs of care decreased sequentially with worsening MRC Brain Tumour prognostic group. Management of patients with the best prognosis (MRC index score of 1-10) cost a median of 16,550 Pounds (range 4572-26,090 Pounds) whilst the median management cost of those in the worst prognostic group (MRC score 34-38) was 6514 Pounds (range 1978-18,360 Pounds). The median cost of each week of survival in the patients with the best outcome (MRC score 1-10) was < 150 Pounds compared to 232 Pounds for each week of survival for patients in the worst prognostic group (MRC score 34-38). This study made no attempt to collect costs of supportive or community-based care. Prospective studies are required to collect such data, as well as assessing the costs effectiveness of alternative treatment strategies.
authors.affiliation: Department of Clinical Neurosciences, Western General Hospital, Edinburgh, UK.
authors.forename: A Z
authors.initials: AZ
authors.lastname: Latif
authors.forename: D
authors.initials: D
authors.lastname: Signorini
authors.forename: A
authors.initials: A
authors.lastname: Gregor
authors.forename: I R
authors.initials: IR
authors.lastname: Whittle
mesh_terms: D001932:Brain Neoplasms / Q000191:economics* / Q000628:therapy; D015331:Cohort Studies; D003362:Cost-Benefit Analysis; D005260:Female; D005910:Glioma / Q000191:economics* / Q000628:therapy; D017721:Hospital Costs / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D016522:Oncology Service, Hospital / Q000191:economics*; D011379:Prognosis; D019057:Quality-Adjusted Life Years; D012606:Scotland; D013222:State Medicine / Q000191:economics*; D015996:Survival Rate